Nucleo

AI for automating oncology CT scan analysis

Website: https://nucleoresearch.com

Cover Block

PUBLIC
Name Nucleo
Tagline AI for automating oncology CT scan analysis
Founded 2022
Stage Seed
Business Model B2B
Industry Healthtech
Technology AI / Machine Learning
Geography Global / Remote-First
Growth Profile Venture Scale
Funding Label Seed (total disclosed ~$4,000,000)

Links

PUBLIC

Executive Summary

PUBLIC Nucleo is a seed-stage startup building AI to automate the analysis of CT scans for oncology, a wedge into a clinical workflow burdened by manual, time-intensive processes [Y Combinator, Unknown]. The company’s proposition, which reportedly delivers segmentation 2,500 times faster than manual methods, targets a clear efficiency gap in radiology and oncology departments [Y Combinator, Unknown]. Founded in 2022 and backed by Y Combinator’s Fall 2025 batch, the company has disclosed a $4 million seed round, though its investor syndicate and founding team remain unlisted in public records [Forbes, November 2025]. Its core technology is described as an agentic platform that provides automated body composition analysis, tumor sizing, and lesion classification from imported scans [Nucleo, Unknown]. The business model is B2B, targeting global hospitals and healthcare providers, with reported collaborations at institutions like Stanford and Cedars-Sinai serving as early, though unverified, signals of clinical engagement [Forbes, November 2025]. Over the next 12-18 months, validation will hinge on moving beyond these initial partnerships to disclosed commercial contracts, peer-reviewed performance data, and clarity around its regulatory pathway, as the current public profile is defined more by potential than by demonstrated commercial traction.

Data Accuracy: YELLOW -- Key claims (funding, YC affiliation) are confirmed by Y Combinator and Forbes, but performance metrics and customer partnerships lack independent verification.

Taxonomy Snapshot

Axis Classification
Stage Seed
Business Model B2B
Industry / Vertical Healthtech
Technology Type AI / Machine Learning
Geography Global / Remote-First
Growth Profile Venture Scale
Funding Seed (total disclosed ~$4,000,000)

Company Overview

PUBLIC

Nucleo was founded in 2022 as a Y Combinator-backed venture focused on applying AI to oncology imaging [Y Combinator]. The company's public narrative positions it as a research-driven entity, operating under the legal name Nucleo Research, Inc. [Startup Seeker]. Headquarters location is not disclosed, consistent with a remote-first or stealth operational model.

Key milestones are sparse in the public record. The company's primary public debut appears to have been its participation in Y Combinator's Fall 2025 batch, where it was featured in a launch post and a subsequent list of startups to watch [Y Combinator] [Forbes, November 2025]. The only confirmed funding event is a $4 million seed round, which sources indicate occurred in 2022, though the lead investor remains undisclosed [Y Combinator].

Beyond its Y Combinator affiliation and seed financing, the company's development timeline is opaque. No subsequent funding announcements, major partnership disclosures, or regulatory clearances have been reported in mainstream tech or healthcare trade press since its founding.

Data Accuracy: YELLOW -- Founding year and YC affiliation are confirmed; funding amount is cited but investor details are not. Key milestones are inferred from limited public launch activity.

Product and Technology

MIXED Nucleo's core product is an AI software platform designed to automate specific, high-effort tasks within oncology CT scan analysis. The company's public materials frame the tool as an agentic workflow for oncologists and radiologists, taking imported CT scans and generating automated insights that would otherwise require manual segmentation and measurement [Y Combinator]. The primary application surfaces are focused on quantitative analysis rather than diagnostic interpretation.

The platform's capabilities, as described by the company, center on three specific outputs. Body composition analysis, including the detection of sarcopenia (muscle wasting), a known prognostic factor in cancer patients. Tumor lesion sizing and volume calculation, providing standardized measurements for target lesions. Lesion classification, distinguishing between target and non-target lesions for tracking purposes [nucleoresearch.com]. Performance claims are significant: the company states the software provides segmentation 2,500 times faster than manual methods, with 98% agreement to expert radiologist assessments [Y Combinator].

Technical architecture and stack details are not publicly disclosed. The absence of a careers page or technical job postings prevents inference from hiring needs. The product appears to be a cloud-based software service, given its described workflow of importing scans and delivering insights, but this is not explicitly confirmed. There is no public announcement of a regulatory clearance, such as FDA 510(k) or CE marking, which would be a critical milestone for clinical deployment in the United States or Europe.

Data Accuracy: ORANGE -- Product claims sourced solely from company and Y Combinator materials; performance metrics and hospital collaborations are unverified by independent press or customer case studies.

Market Research

PUBLIC The demand for automated medical image analysis is accelerating, driven by persistent radiologist shortages and the growing volume of diagnostic scans.

Quantifying the precise market for AI in oncology CT analysis is challenging with the available public data. No third-party TAM, SAM, or SOM figures specific to Nucleo's niche are cited in the research. However, analogous market sizing for broader AI in medical imaging provides a relevant frame of reference. Reports from firms like Grand View Research and MarketsandMarkets project the global AI in medical imaging market to reach values from $1.5 billion to over $4.5 billion by 2030, with compound annual growth rates estimated between 26% and 30% [Grand View Research] [MarketsandMarkets]. These figures encompass all imaging modalities and clinical applications, suggesting the oncology-specific segment addressed by Nucleo is a meaningful subset.

Demand drivers are well-documented. The global shortage of radiologists creates a structural bottleneck, increasing the appeal of workflow automation tools that can act as a force multiplier [Forbes]. Concurrently, the volume of diagnostic imaging continues to grow, particularly in oncology where serial CT scans are standard for treatment monitoring. This combination of constrained supply and rising demand creates a clear wedge for software that promises efficiency gains. A secondary tailwind is the increasing clinical validation of AI algorithms for specific tasks, such as sarcopenia detection, which is gaining recognition as a prognostic marker in cancer care.

Adjacent and substitute markets are significant. Nucleo's product competes not only with manual analysis but also with a growing field of general-purpose radiology AI platforms offered by large incumbents like GE HealthCare and Siemens Healthineers, as well as specialized software from electronic health record vendors. The key adjacent market is the broader oncology diagnostics and clinical decision support software sector, where purchasing decisions are often bundled. Regulatory forces, primarily FDA clearance for software as a medical device (SaMD), represent a critical gating factor for commercial deployment in the United States, though the company's current collaborations with academic hospitals may operate under a research-use framework.

Metric Value
AI in Medical Imaging (Global) 1.5 $B
Projected Growth Rate (CAGR) 26 %

The projected market size and growth rate for the broader AI medical imaging sector indicate a large and rapidly expanding addressable market, though Nucleo's specific share within it remains unquantified.

Data Accuracy: YELLOW -- Market sizing is based on analogous, third-party industry reports for the broader AI medical imaging sector; specific TAM for oncology CT automation is not publicly available.

Competitive Landscape

MIXED

Nucleo enters a market defined by large-scale platform vendors and specialized point solutions, positioning itself as a workflow automation layer for oncology-specific CT analysis. The competitive map is not defined by a single head-to-head rival but by a collection of incumbents and challengers each attacking a different part of the radiology AI stack.

From a segment perspective, competition breaks into three tiers. The first tier consists of enterprise imaging platforms from companies like GE HealthCare, Siemens Healthineers, and Philips. These are the entrenched incumbents, offering comprehensive PACS and imaging suites where AI is an integrated feature. Their advantage is distribution and the existing capital expenditure relationship with hospital systems, but their innovation in specialized oncology workflows can be slower. The second tier is the crowded field of FDA-cleared radiology AI startups, such as Aidoc for triage or Viz.ai for stroke. These companies have proven commercial models and regulatory pathways, but they typically focus on acute, high-volume conditions (e.g., pulmonary embolism, intracranial hemorrhage) rather than the longitudinal, measurement-intensive workflow of oncology. The third tier comprises academic and open-source tools used for research, which lack the polish, support, and integration required for clinical deployment.

Nucleo's claimed edge today rests on a narrow technical wedge: automating the time-consuming, manual tasks of tumor volumetrics and body composition analysis like sarcopenia detection. The company cites a 2,500x speed improvement over manual segmentation with 98% expert agreement [Y Combinator]. If validated, this performance in a specific, high-friction workflow could be its initial defensibility. However, this edge is perishable. It is a software and algorithm advantage, not a structural moat like proprietary data or regulatory exclusivity. Larger platforms could develop or acquire similar capabilities, and other AI startups could pivot into the oncology measurement niche once its commercial viability is demonstrated. The company's affiliation with Y Combinator provides talent and network access, but in healthtech, capital and regulatory expertise are more durable advantages, and Nucleo's investor base remains undisclosed.

The company's most significant exposure is its lack of commercial and regulatory footprint. It has not announced any FDA clearances, which are table stakes for clinical deployment in the U.S. market. This leaves it vulnerable to competitors with cleared products for similar indications. For instance, a company like RadNet, with its deep learning division and extensive imaging center network, could move into this space with established sales channels. Furthermore, Nucleo's focus on pure software analysis makes it dependent on hospital IT integration, a notoriously slow process where platform vendors hold the use. Its reported collaborations with institutions like Stanford and Cedars-Sinai [Forbes] are promising but do not constitute commercial contracts or deployed revenue.

The most plausible 18-month scenario involves increased segmentation within the oncology AI segment. If Nucleo can secure an initial FDA clearance and convert its pilot collaborations into paid contracts, it becomes an attractive acquisition target for a larger platform seeking to bolster its oncology suite. The "winner" in this case would be a nimble specialist that proves the market for automated oncology metrics. Conversely, if the company fails to transition from research collaborations to revenue-generating deployments, it becomes a "loser" by remaining in a perpetual pilot phase, vulnerable to being outflanked by better-funded competitors who replicate its technical approach while leveraging superior commercial engines. The competitive outcome will hinge less on algorithm performance and more on execution in sales, regulation, and integration.

Data Accuracy: ORANGE -- Competitive analysis is inferred from market structure; specific competitor claims and Nucleo's technical differentiator are sourced solely from company and YC materials.

Opportunity

PUBLIC The prize for Nucleo is a foundational role in the quantitative, AI-driven future of oncology care, where automated CT analysis becomes a standard, reimbursable component of treatment planning.

The headline opportunity is to become the default quantitative imaging platform for oncology clinical trials and, subsequently, routine care. The wedge is not just a faster tool for radiologists but a new data layer for drug developers and hospital systems. The company's reported focus on specific, high-value clinical tasks like sarcopenia detection and tumor volume measurement [Y Combinator] aligns with endpoints increasingly used in pharmaceutical research. If Nucleo's software can deliver consistent, regulatory-grade measurements, it could embed itself as a required service in trial protocols, creating a durable revenue stream that precedes broader hospital adoption. The initial reported work with leading academic medical centers [Forbes] provides a plausible entry point for this path, as these institutions often partner with biopharma on early-stage research.

Growth beyond a point-solution requires navigating specific, concrete scenarios. The following table outlines two plausible paths to scale, each tied to a visible catalyst.

Scenario What happens Catalyst Why it's plausible
Clinical Trial Standard Nucleo's software is adopted as a core imaging lab for oncology trials, measuring tumor response and body composition across hundreds of study sites. A partnership with a major Contract Research Organization (CRO) or a top-20 pharmaceutical company to validate its algorithms for a specific cancer type. Academic medical centers like Stanford and Weill Cornell [Forbes] are frequent sites for early-phase trials; a successful pilot could be leveraged for a formal commercial partnership.
Hospital Workflow Mandate A major U.S. health system mandates Nucleo for all quantitative oncology CT reads, displacing manual measurements and legacy software. A large integrated delivery network (IDN) publishes a study showing Nucleo reduces radiologist burnout and improves measurement consistency, leading to a system-wide contract. The claimed 2,500x speed improvement and 98% expert agreement [Y Combinator] directly address operational pain points (throughput) and clinical concerns (accuracy) that drive purchasing decisions.

Compounding for Nucleo would manifest as a data and distribution flywheel. Each new hospital deployment generates more diverse, real-world CT scans, which can be used to refine and validate the AI models for broader patient populations and additional cancer types. This improved performance could then be leveraged to secure regulatory clearances (e.g., FDA 510(k)), which in turn lowers the adoption barrier for more conservative health systems. Furthermore, integration into a major health system's electronic health record (EHR) creates significant switching costs, locking in the account and providing a beachhead for selling additional AI modules. While there is no public evidence this flywheel is yet in motion, the nature of the product and the hospital sales cycle suggests this is the intended scaling mechanism.

To size the win, consider the trajectory of a comparable company: PathAI, a provider of AI-powered pathology tools for biopharma and diagnostics. PathAI reached a valuation of approximately $1.3 billion following its Series C round in 2021 [Crunchbase, November 2021], built on a similar model of serving both clinical research and diagnostic markets. If Nucleo successfully executes the Clinical Trial Standard scenario and captures a meaningful portion of the oncology imaging analysis market for drug development,a multi-billion dollar segment,a PathAI-scale outcome is a credible comparable (scenario, not a forecast). The total addressable market expands significantly if it also penetrates routine hospital care, though that represents a longer-term, more competitive endeavor.

Data Accuracy: YELLOW -- Opportunity analysis is based on reported product claims and a single secondary source citing hospital collaborations; growth scenarios are plausible extrapolations but lack direct confirming evidence.

Sources

PUBLIC

  1. [Y Combinator] Nucleo | Y Combinator | https://www.ycombinator.com/companies/nucleo

  2. [Forbes, November 2025] The Top Startups To Watch From Y Combinator’s Fall 2025 Batch | https://www.forbes.com/sites/dariashunina/2025/11/13/the-top-startups-to-watch-from-y-combinators-fall-2025-batch/

  3. [Nucleo] Nucleo | https://nucleoresearch.com

  4. [Startup Seeker] Nucleo Research, Inc. | https://startup-seeker.com/company/nucleoresearch~com

  5. [Grand View Research] AI in Medical Imaging Market Size, Share & Trends Analysis Report | URL not provided in structured facts.

  6. [MarketsandMarkets] AI in Medical Imaging Market by Component, Application, End User - Global Forecast to 2030 | URL not provided in structured facts.

  7. [Crunchbase, November 2021] PathAI Raises $165M Series C | URL not provided in structured facts.

Articles about Nucleo

View on Startuply.vc